AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBIO
  4. [Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

BridgeBio Pharma director Andrea Ellis received new equity compensation grants on June 20, 2025, consisting of two components:

  • 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, increasing total direct stock ownership to 18,589 shares
  • 8,425 Stock Options with an exercise price of $41.73 and expiration date of June 19, 2035

Both grants follow a 3-year vesting schedule with one-third vesting annually starting June 20, 2025, contingent on continued board service through June 20, 2028. The equity awards were issued under the company's 2021 Amended and Restated Stock Option and Incentive Plan, representing standard director compensation aligned with long-term shareholder interests.

Andrea Ellis, membro del consiglio di amministrazione di BridgeBio Pharma, ha ricevuto nuove assegnazioni di compensi azionari il 20 giugno 2025, suddivise in due parti:

  • 6.589 Unit脿 Azionarie Vincolate (RSU) con prezzo di esercizio pari a 0$, portando la propriet脿 diretta totale a 18.589 azioni
  • 8.425 Opzioni su Azioni con prezzo di esercizio di 41,73$ e scadenza il 19 giugno 2035

Entrambe le assegnazioni prevedono un piano di maturazione triennale, con un terzo delle azioni che maturano ogni anno a partire dal 20 giugno 2025, subordinato alla permanenza nel consiglio fino al 20 giugno 2028. Le azioni sono state emesse secondo il Piano Azionario e di Incentivi modificato e riformulato del 2021 dell'azienda, rappresentando una compensazione standard per i direttori, in linea con gli interessi a lungo termine degli azionisti.

Andrea Ellis, directora de BridgeBio Pharma, recibi贸 nuevas concesiones de compensaci贸n en acciones el 20 de junio de 2025, que constan de dos componentes:

  • 6,589 Unidades de Acciones Restringidas (RSU) con precio de ejercicio de $0, aumentando la propiedad directa total a 18,589 acciones
  • 8,425 Opciones sobre Acciones con un precio de ejercicio de $41.73 y fecha de vencimiento el 19 de junio de 2035

Ambas concesiones siguen un programa de adquisici贸n de derechos de 3 a帽os, con un tercio que se adquiere anualmente a partir del 20 de junio de 2025, condicionado a la continuidad en el consejo hasta el 20 de junio de 2028. Las acciones se emitieron bajo el Plan de Opciones sobre Acciones e Incentivos Enmendado y Reformulado de 2021 de la compa帽铆a, representando una compensaci贸n est谩ndar para directores alineada con los intereses a largo plazo de los accionistas.

BridgeBio Pharma 鞚挫偓 Andrea Ellis電� 2025雲� 6鞗� 20鞚检棎 霊� 臧�歆� 甑劚 鞖旍唽搿� 鞚措（鞏挫 靸堧鞖� 欤检嫕 氤挫儊 攵�鞐ゼ 氚涭晿鞀惦媹雼�:

  • 6,589 鞝滍暅 欤检嫕 雼渼(RSU)搿� 頄夓偓 臧�瓴╈潃 0雼煬鞚措┌, 齑� 歆侅爲 欤检嫕 氤挫湢霟夓澊 18,589欤茧 歃濌皜頃�
  • 8,425 欤检嫕 鞓奠厴鞙茧 頄夓偓 臧�瓴╈潃 $41.73, 毵岆鞚检潃 2035雲� 6鞗� 19鞚�

霊� 攵�鞐� 氇憪 3雲� 甓岆Μ 頇曥爼 鞚检爼鞚� 霐半ゴ氅�, 2025雲� 6鞗� 20鞚茧秬韯� 毵る厔 3攵勳潣 1鞌� 甓岆Μ臧� 頇曥爼霅橂┌, 2028雲� 6鞗� 20鞚缄箤歆� 鞚挫偓須� 頇滊彊鞚� 瓿勳啀霅橂姅 臁瓣贝鞛呺媹雼�. 鞚� 欤检嫕 氤挫儊鞚� 須岇偓鞚� 2021雲� 臧滌爼 氚� 鞛瀾靹彪悳 欤检嫕 鞓奠厴 氚� 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 氚滍枆霅橃棃鞙茧┌, 鞛リ赴 欤检＜ 鞚挫澋鞐� 攵�頃╉晿電� 響滌 鞚挫偓 氤挫儊鞛呺媹雼�.

Andrea Ellis, administratrice de BridgeBio Pharma, a re莽u de nouvelles attributions de r茅mun茅ration en actions le 20 juin 2025, comprenant deux volets :

  • 6 589 unit茅s d鈥檃ctions restreintes (RSU) avec un prix d鈥檈xercice de 0 $, portant la d茅tention directe totale 脿 18 589 actions
  • 8 425 options d鈥檃chat d鈥檃ctions avec un prix d鈥檈xercice de 41,73 $ et une date d鈥檈xpiration au 19 juin 2035

Les deux attributions suivent un calendrier d鈥檃cquisition sur 3 ans avec un tiers des actions acquises chaque ann茅e 脿 partir du 20 juin 2025, sous r茅serve de la poursuite du mandat au conseil d鈥檃dministration jusqu鈥檃u 20 juin 2028. Les actions ont 茅t茅 茅mises dans le cadre du Plan d鈥檕ptions d鈥檃chat d鈥檃ctions et d鈥檌ncitations modifi茅 et refondu de 2021 de la soci茅t茅, constituant une r茅mun茅ration standard pour les administrateurs, align茅e sur les int茅r锚ts 脿 long terme des actionnaires.

Andrea Ellis, Direktorin von BridgeBio Pharma, erhielt am 20. Juni 2025 neue Aktienverg眉tungen, bestehend aus zwei Komponenten:

  • 6.589 Restricted Stock Units (RSUs) mit einem Aus眉bungspreis von 0 $, wodurch der direkte Aktienbesitz auf insgesamt 18.589 Aktien steigt
  • 8.425 Aktienoptionen mit einem Aus眉bungspreis von 41,73 $ und Ablaufdatum am 19. Juni 2035

Beide Vergaben folgen einem 3-j盲hrigen Vesting-Plan, bei dem jeweils ein Drittel j盲hrlich ab dem 20. Juni 2025 vestet, vorausgesetzt die Mitgliedschaft im Vorstand besteht bis zum 20. Juni 2028 fort. Die Aktien wurden im Rahmen des 2021 ge盲nderten und neu gefassten Aktienoptions- und Anreizplans des Unternehmens ausgegeben und stellen eine standardm盲脽ige Direktorenverg眉tung dar, die mit den langfristigen Interessen der Aktion盲re in Einklang steht.

Positive
  • None.
Negative
  • None.

Andrea Ellis, membro del consiglio di amministrazione di BridgeBio Pharma, ha ricevuto nuove assegnazioni di compensi azionari il 20 giugno 2025, suddivise in due parti:

  • 6.589 Unit脿 Azionarie Vincolate (RSU) con prezzo di esercizio pari a 0$, portando la propriet脿 diretta totale a 18.589 azioni
  • 8.425 Opzioni su Azioni con prezzo di esercizio di 41,73$ e scadenza il 19 giugno 2035

Entrambe le assegnazioni prevedono un piano di maturazione triennale, con un terzo delle azioni che maturano ogni anno a partire dal 20 giugno 2025, subordinato alla permanenza nel consiglio fino al 20 giugno 2028. Le azioni sono state emesse secondo il Piano Azionario e di Incentivi modificato e riformulato del 2021 dell'azienda, rappresentando una compensazione standard per i direttori, in linea con gli interessi a lungo termine degli azionisti.

Andrea Ellis, directora de BridgeBio Pharma, recibi贸 nuevas concesiones de compensaci贸n en acciones el 20 de junio de 2025, que constan de dos componentes:

  • 6,589 Unidades de Acciones Restringidas (RSU) con precio de ejercicio de $0, aumentando la propiedad directa total a 18,589 acciones
  • 8,425 Opciones sobre Acciones con un precio de ejercicio de $41.73 y fecha de vencimiento el 19 de junio de 2035

Ambas concesiones siguen un programa de adquisici贸n de derechos de 3 a帽os, con un tercio que se adquiere anualmente a partir del 20 de junio de 2025, condicionado a la continuidad en el consejo hasta el 20 de junio de 2028. Las acciones se emitieron bajo el Plan de Opciones sobre Acciones e Incentivos Enmendado y Reformulado de 2021 de la compa帽铆a, representando una compensaci贸n est谩ndar para directores alineada con los intereses a largo plazo de los accionistas.

BridgeBio Pharma 鞚挫偓 Andrea Ellis電� 2025雲� 6鞗� 20鞚检棎 霊� 臧�歆� 甑劚 鞖旍唽搿� 鞚措（鞏挫 靸堧鞖� 欤检嫕 氤挫儊 攵�鞐ゼ 氚涭晿鞀惦媹雼�:

  • 6,589 鞝滍暅 欤检嫕 雼渼(RSU)搿� 頄夓偓 臧�瓴╈潃 0雼煬鞚措┌, 齑� 歆侅爲 欤检嫕 氤挫湢霟夓澊 18,589欤茧 歃濌皜頃�
  • 8,425 欤检嫕 鞓奠厴鞙茧 頄夓偓 臧�瓴╈潃 $41.73, 毵岆鞚检潃 2035雲� 6鞗� 19鞚�

霊� 攵�鞐� 氇憪 3雲� 甓岆Μ 頇曥爼 鞚检爼鞚� 霐半ゴ氅�, 2025雲� 6鞗� 20鞚茧秬韯� 毵る厔 3攵勳潣 1鞌� 甓岆Μ臧� 頇曥爼霅橂┌, 2028雲� 6鞗� 20鞚缄箤歆� 鞚挫偓須� 頇滊彊鞚� 瓿勳啀霅橂姅 臁瓣贝鞛呺媹雼�. 鞚� 欤检嫕 氤挫儊鞚� 須岇偓鞚� 2021雲� 臧滌爼 氚� 鞛瀾靹彪悳 欤检嫕 鞓奠厴 氚� 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 氚滍枆霅橃棃鞙茧┌, 鞛リ赴 欤检＜ 鞚挫澋鞐� 攵�頃╉晿電� 響滌 鞚挫偓 氤挫儊鞛呺媹雼�.

Andrea Ellis, administratrice de BridgeBio Pharma, a re莽u de nouvelles attributions de r茅mun茅ration en actions le 20 juin 2025, comprenant deux volets :

  • 6 589 unit茅s d鈥檃ctions restreintes (RSU) avec un prix d鈥檈xercice de 0 $, portant la d茅tention directe totale 脿 18 589 actions
  • 8 425 options d鈥檃chat d鈥檃ctions avec un prix d鈥檈xercice de 41,73 $ et une date d鈥檈xpiration au 19 juin 2035

Les deux attributions suivent un calendrier d鈥檃cquisition sur 3 ans avec un tiers des actions acquises chaque ann茅e 脿 partir du 20 juin 2025, sous r茅serve de la poursuite du mandat au conseil d鈥檃dministration jusqu鈥檃u 20 juin 2028. Les actions ont 茅t茅 茅mises dans le cadre du Plan d鈥檕ptions d鈥檃chat d鈥檃ctions et d鈥檌ncitations modifi茅 et refondu de 2021 de la soci茅t茅, constituant une r茅mun茅ration standard pour les administrateurs, align茅e sur les int茅r锚ts 脿 long terme des actionnaires.

Andrea Ellis, Direktorin von BridgeBio Pharma, erhielt am 20. Juni 2025 neue Aktienverg眉tungen, bestehend aus zwei Komponenten:

  • 6.589 Restricted Stock Units (RSUs) mit einem Aus眉bungspreis von 0 $, wodurch der direkte Aktienbesitz auf insgesamt 18.589 Aktien steigt
  • 8.425 Aktienoptionen mit einem Aus眉bungspreis von 41,73 $ und Ablaufdatum am 19. Juni 2035

Beide Vergaben folgen einem 3-j盲hrigen Vesting-Plan, bei dem jeweils ein Drittel j盲hrlich ab dem 20. Juni 2025 vestet, vorausgesetzt die Mitgliedschaft im Vorstand besteht bis zum 20. Juni 2028 fort. Die Aktien wurden im Rahmen des 2021 ge盲nderten und neu gefassten Aktienoptions- und Anreizplans des Unternehmens ausgegeben und stellen eine standardm盲脽ige Direktorenverg眉tung dar, die mit den langfristigen Interessen der Aktion盲re in Einklang steht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ellis Andrea
(Last) (First) (Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 A(1) 6,589 A $0(2) 18,589 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $41.73 06/20/2025 A 8,425 (3) 06/19/2035 Common Stock 8,425 $0 8,425 D
Explanation of Responses:
1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
/s/ Andrea J. Ellis 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many BBIO restricted stock units (RSUs) did Director Andrea Ellis receive on June 20, 2025?

Director Andrea Ellis received 6,589 restricted stock units (RSUs) on June 20, 2025, as part of BridgeBio's 2021 Amended and Restated Stock Option and Incentive Plan.

What is the vesting schedule for BBIO Director Andrea Ellis's new stock options?

The stock options will vest in three equal annual installments over three years, with one-third vesting each year after June 20, 2025. Full vesting will occur on June 20, 2028, subject to Ellis's continued service on BridgeBio's board of directors.

What is the exercise price of BBIO stock options granted to Director Ellis in June 2025?

The stock options were granted with an exercise price of $41.73 per share and expire on June 19, 2035.

How many BBIO shares does Andrea Ellis own after the June 2025 stock grant?

Following the transaction, Andrea Ellis directly owns 18,589 shares of BBIO common stock, plus 8,425 stock options that were newly granted.

What is the vesting schedule for BBIO Director Ellis's restricted stock units granted in June 2025?

The RSUs will vest in three equal annual installments, with one-third vesting each year after June 20, 2025. Full vesting will occur on June 20, 2028, subject to Ellis's continued service on BridgeBio's board of directors.
Stock BBIO logo
Bridgebio Pharma

NASDAQ:BBIO

BBIO Rankings

#930 Ranked by Market Cap
N/A Ranked by Dividends

BBIO Latest News

Aug 5, 2025
BridgeBio Reports Second Quarter 2025聽Financial Results and Business Updates
Jul 23, 2025
Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1
Jul 22, 2025
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
Jun 30, 2025
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA庐 European Royalty
Jun 26, 2025
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

BBIO Latest SEC Filings

Aug 12, 2025
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity
Aug 11, 2025
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity
Aug 11, 2025
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity
Aug 11, 2025
[144] BridgeBio Pharma, Inc. SEC Filing
Aug 8, 2025
[144] BridgeBio Pharma, Inc. SEC Filing

BBIO Stock Data

9.22B
164.71M
4.96%
97.09%
10.26%
Biotechnology
Pharmaceutical Preparations
United States
PALO ALTO